Cargando…

Preliminary results of using ALAnerv® in subacute motor incomplete paraplegics

Rationale: To assess whether using ALAnerv® contributes to improvements of outcomes obtained in post SCI patients. Objective: A prospective controlled clinical survey also to evaluate the safety and efficacy of ALAnerv® (2cps/ day for 28 days) in motor incomplete (AIS/ Frankel C) paraplegic subacute...

Descripción completa

Detalles Bibliográficos
Autores principales: Andone, I, Anghelescu, A, Daia, C, Onose, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Carol Davila University Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556909/
https://www.ncbi.nlm.nih.gov/pubmed/26351530
_version_ 1782388416899448832
author Andone, I
Anghelescu, A
Daia, C
Onose, G
author_facet Andone, I
Anghelescu, A
Daia, C
Onose, G
author_sort Andone, I
collection PubMed
description Rationale: To assess whether using ALAnerv® contributes to improvements of outcomes obtained in post SCI patients. Objective: A prospective controlled clinical survey also to evaluate the safety and efficacy of ALAnerv® (2cps/ day for 28 days) in motor incomplete (AIS/ Frankel C) paraplegic subacute patients. Methods and results: 59 patients divided in study (treated with ALAnerv®) and control, groups. This survey’s follow-up duration was of 28 days. Most of the studied patients were mid-aged (mean 43.75 years old) and respectively, men (64,29% in the study group; 58,06% in controls). We used descriptive statistics (functions: minimum, maximum, mean, median, standard deviation) and for related comparisons, parametric (Student t) and non-parametric (Mann-Whitney, Fisher’s exact, chi-square) tests. The primary end-point: AIS motor values’ evolution (P= 0.015 - Mann-Whitney), showed that patients treated with ALAnerv® – vs. controls – had a statistically significant better increase of such scores at discharge. Paraclinical parameters, mainly exploring systemic inflammatory status (secondary end-point): ESR dynamics (P=0.13) had no statistical significance; the plasma leucocytes number (P=0.018), the neutrophils’ percentage (P=0.001) and fibrinogenemia (P= 0,017) proved in the treated group to have a statistically significant better evolution. We used “Statistical Package for Social Sciences” (SPSS). Discussion: As there is actually no effective curative solution for the devastating pathology following SCI, any medical approach susceptible to bring even limited improvements, such as treatment with ALAnerv® seemed to have proven, is worth being surveyed, under strict circumstances of ethics and research methodology. Considering the necessity for more statistical power concerning primary, secondary end-points, and safety issues, as well, continuing this research is needed. Abbreviations: SCI = spinal cord injury, TSCI = traumatic spinal cord injury, BBB = blood brain barrier, CNS = central nervous system, SC = spinal cord, NSAIDs = non-steroidal anti-inflammatory drugs, SAIDs = steroidal anti-inflammatory drugs, AIS = American Spinal Injury Association Impairment Scale, SPSS = Statistical Package for Social Sciences, BATEH = Bagdasar-Arseni Teaching Emergency Hospital
format Online
Article
Text
id pubmed-4556909
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Carol Davila University Press
record_format MEDLINE/PubMed
spelling pubmed-45569092015-09-08 Preliminary results of using ALAnerv® in subacute motor incomplete paraplegics Andone, I Anghelescu, A Daia, C Onose, G J Med Life Original Articles Rationale: To assess whether using ALAnerv® contributes to improvements of outcomes obtained in post SCI patients. Objective: A prospective controlled clinical survey also to evaluate the safety and efficacy of ALAnerv® (2cps/ day for 28 days) in motor incomplete (AIS/ Frankel C) paraplegic subacute patients. Methods and results: 59 patients divided in study (treated with ALAnerv®) and control, groups. This survey’s follow-up duration was of 28 days. Most of the studied patients were mid-aged (mean 43.75 years old) and respectively, men (64,29% in the study group; 58,06% in controls). We used descriptive statistics (functions: minimum, maximum, mean, median, standard deviation) and for related comparisons, parametric (Student t) and non-parametric (Mann-Whitney, Fisher’s exact, chi-square) tests. The primary end-point: AIS motor values’ evolution (P= 0.015 - Mann-Whitney), showed that patients treated with ALAnerv® – vs. controls – had a statistically significant better increase of such scores at discharge. Paraclinical parameters, mainly exploring systemic inflammatory status (secondary end-point): ESR dynamics (P=0.13) had no statistical significance; the plasma leucocytes number (P=0.018), the neutrophils’ percentage (P=0.001) and fibrinogenemia (P= 0,017) proved in the treated group to have a statistically significant better evolution. We used “Statistical Package for Social Sciences” (SPSS). Discussion: As there is actually no effective curative solution for the devastating pathology following SCI, any medical approach susceptible to bring even limited improvements, such as treatment with ALAnerv® seemed to have proven, is worth being surveyed, under strict circumstances of ethics and research methodology. Considering the necessity for more statistical power concerning primary, secondary end-points, and safety issues, as well, continuing this research is needed. Abbreviations: SCI = spinal cord injury, TSCI = traumatic spinal cord injury, BBB = blood brain barrier, CNS = central nervous system, SC = spinal cord, NSAIDs = non-steroidal anti-inflammatory drugs, SAIDs = steroidal anti-inflammatory drugs, AIS = American Spinal Injury Association Impairment Scale, SPSS = Statistical Package for Social Sciences, BATEH = Bagdasar-Arseni Teaching Emergency Hospital Carol Davila University Press 2015 /pmc/articles/PMC4556909/ /pubmed/26351530 Text en ©Carol Davila University Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Andone, I
Anghelescu, A
Daia, C
Onose, G
Preliminary results of using ALAnerv® in subacute motor incomplete paraplegics
title Preliminary results of using ALAnerv® in subacute motor incomplete paraplegics
title_full Preliminary results of using ALAnerv® in subacute motor incomplete paraplegics
title_fullStr Preliminary results of using ALAnerv® in subacute motor incomplete paraplegics
title_full_unstemmed Preliminary results of using ALAnerv® in subacute motor incomplete paraplegics
title_short Preliminary results of using ALAnerv® in subacute motor incomplete paraplegics
title_sort preliminary results of using alanerv® in subacute motor incomplete paraplegics
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556909/
https://www.ncbi.nlm.nih.gov/pubmed/26351530
work_keys_str_mv AT andonei preliminaryresultsofusingalanervinsubacutemotorincompleteparaplegics
AT anghelescua preliminaryresultsofusingalanervinsubacutemotorincompleteparaplegics
AT daiac preliminaryresultsofusingalanervinsubacutemotorincompleteparaplegics
AT onoseg preliminaryresultsofusingalanervinsubacutemotorincompleteparaplegics